drugset / Trial / NCT03713957
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Phase 2
Completed
79 enrolled
Alkahest, Inc.
Michael J. Fox Foundation for Parkinson's Research · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.
Timeline
- Start
- 2018-11-12
- Primary completion
- 2020-07-20
- Completion
- 2020-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GRF6021 | Protein / enzyme biologic | — | Intravenous |